Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Regeneron, Sanofi Say Japan Grants Marketing Authorization for Dupixent

, MT Newswires - 3:22 AM ET 3/28/2025 default

03:22 AM EDT, 03/28/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Friday their Dupixent, or dupilumab, drug was approved in Japan for the treatment of chronic obstructive pulmonary disease, or COPD, in adults.

COPD is a chronic respiratory disease that damages the lungs and causes lung function to decline.

The Japanese Ministry of Health, Labour and Welfare granted marketing and manufacturing authorization for the drug based on data from a phase 3 trial. The study showed the product significantly reduced exacerbations and improved lung function compared with placebo, the companies said.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.